Friday, 20 Sep 2019

You are here

RheumNow Week in Review – 22 July 2016

Highlights from this week on RheumNow.com include:

  1. In Tofacitinib developmental trials in RA and Psoriasis, there were 1821 women of child-bearing age who were exposed; 47 became pregnant (33 monoRx). There were no deaths and one congenital malformation (1 Pulmonic valve stenosis), 7 Spontaneous Abortions. http://buff.ly/2azDHwd
  2. BMS has a new autoinjector for abatacept (ORENCIA) called "ClickJect" with a 15 sec delivery duration https://t.co/6QHIqK51Pj
  3. Between 10-50% of colorectal cancer patients have a positive ANA by either EIA or IIF. Small study but instructive. https://t.co/WWMbH3J4Vw
  4. Pirfenidone is FDA approved for IPF. Open label study 63 PSS patients with IPF show it tolerable and safe but no effect on outcomes https://t.co/j2ujvmfMnF
  5. NEJM article by Drs. Taurog & Colbert review ankylosing spondylitis & Spondyloarthritis. https://t.co/L6lQSi9Gyn
  6. RWCS Pearl: Dapsone can be of benefit in SCLE patients who do not respond to antimalarials. https://t.co/5cOXVH42Xi
  7. WEGENT compared outcomes in 112 GPA & MPA patients; Imuran & MTX had similar 10 yr survival, relapse rates, & toxicities https://t.co/dIl4wnsRzY
  8. Adherence to T2T in 198 early RA pts had no effect on Xrays or 12 mos DAS, but significantly improved DAS & functional outcomes at 3 yrs. https://t.co/XrXhnEkkUl
  9. MTX in Psoriatic arthritis achieves MDA – minimal disease activity criteria in <20%. MDA defined as 5 or more of the following 7 criteria: SJC, PASI, entheses≤1, BSA≤3%, HAQ≤0.5, pt global≤20, Pt pain≤15. https://t.co/dO6qyys8yy
  10. Epigenetic Changes to Inflammasome Found in Autoinflammatory Syndromes. 
  11. DEXA Still Needed While on Bisphosphonates: a study of 6629 Canadian women with osteoporosis taking bisphosphonates finds ~20% have decrease in bone density on medication
  12. Prevalence of Spondyloarthropathy in Fibromyalgia. Sacroiliitis found in 8% of 99 FM patients. Axial SpA found in 10%. Inflammatory MRI imaging changes found in 17% to 25% of patients. 
  13. Will Patent Extensions Delay Biosimilar Arrivals
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

RheumNow Podcast – Believe in Vitamin D or Rituximab? (9.20.19)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

RheumNow Podcast – The End of Arthritis (9.13.19)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

RheumNow Podcast – Do’s and Don’ts in Spondylitis (9.5.19)

Dr. Jack Cush reviews the news and important research published in the last two weeks on RheumNow.com.

Influenza Vaccination Update

FDA's Vaccines and Related Biological Products Advisory Committee met in Silver Spring, Maryland, on March 6 and 22, 2019, to select the influenza viruses for the composition of the influenza vaccine for the 2019-2020 U.S. influenza season.

RheumNow Podcast - I Wanna New Drug (8-30-19)

Dr. Jack Cush vents on choosing new therapies in rheumatoid arthritis.